Abstract 1665P
Background
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Many prognostic factors have been identified in western series. We aimed to identify risk factors associated with outcome in children with RMS in a cohort of Tunisian patients treated in Salah Azaiez Institute.
Methods
Pretreatment characteristics of children with RMS, included in the registry of Salah Azaiez Institute between January 1994 and December 2016, were examined to study the children’s prognosis. We studied the correlation between the clinical factors, the disease-free survival (DFS) and the overall survival (OS). These factors were: age, histology, nodal status, tumor size, site of primary, post surgical group (IRS), site(s) of metastatic disease and treatments received.
Results
Our study included 100 patients. The mean of follow up was 30 months with a range of 1 to 206 months. The 5-year OS and DFS were 45.5% and 26%, respectively. By univariate analysis, 5-year OS was significantly and adversely influenced by 3 factors which were: location of primary tumor in unfavorable site (parameningeal only), tumor size > 4 cm and positive regional nodes with p values 0.04, 0.05 and 0.04, respectively. Radiotherapy (RT) for patients with localised RMS mainly the post surgical RT were associated with a good prognosis in OS p= 0.009 and 0.05, respectively. The prognostic value of age, histology, primary site and IRS group failed to be significant. By multivariate analysis, OS was strongly correlated only to radiotherapy in localised RMS p=0.03, Odds Ratio(OR) =3.1, confidence interval (IC) 95% [1.05-9.3]. The predictive factors in DFS by univariate analysis were: chemotherapy, radiotherapy and post surgical RT with p 0.02, 0.003 and 0.01, respectively. The surgery which is a key treatement of the RMS failed to be a significant factor. In multivariate analysis, we didn`t found any factor significantly correlated to the DFS.
Conclusions
This analysis identified subsets of pediatric patients with rhabdomyosaroma in Tunisia with different outcomes to current therapy. In comparison with the literature data, we had to improve the prognosis of our patients by making the treatement more personalized, encouraging research in new medicines and molecular study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Salah Azaiez Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.